Arcus Biosciences, Inc. (RCUS)
NYSE: RCUS · Real-Time Price · USD
9.93
-0.13 (-1.29%)
Aug 14, 2025, 11:39 AM - Market open
Arcus Biosciences Balance Sheet
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2016 - 2019 |
|---|---|---|---|---|---|---|---|
Period Ending | Jun '25 Jun 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2016 - 2019 |
| Cash & Equivalents | 248 | 150 | 127 | 206 | 148 | 173.42 | Upgrade
|
| Short-Term Investments | 663 | 828 | 632 | 803 | 351 | 555.23 | Upgrade
|
| Cash & Short-Term Investments | 911 | 978 | 759 | 1,009 | 499 | 728.65 | Upgrade
|
| Cash Growth | -5.99% | 28.85% | -24.78% | 102.20% | -31.52% | 287.02% | Upgrade
|
| Accounts Receivable | 15 | 20 | 38 | 39 | 745 | 1.05 | Upgrade
|
| Other Receivables | 5 | 5 | 4 | 4 | 2 | 0.65 | Upgrade
|
| Receivables | 20 | 25 | 42 | 43 | 747 | 1.7 | Upgrade
|
| Prepaid Expenses | 15 | 13 | 30 | 15 | 16 | 5.47 | Upgrade
|
| Total Current Assets | 946 | 1,016 | 831 | 1,067 | 1,262 | 735.82 | Upgrade
|
| Property, Plant & Equipment | 44 | 112 | 143 | 135 | 137 | 23.59 | Upgrade
|
| Long-Term Investments | 16 | 14 | 107 | 129 | 182 | 6.44 | Upgrade
|
| Other Long-Term Assets | 69 | 8 | 14 | 14 | 11 | 6.45 | Upgrade
|
| Total Assets | 1,075 | 1,150 | 1,095 | 1,345 | 1,592 | 772.29 | Upgrade
|
| Accounts Payable | 29 | 18 | 17 | 20 | 10 | 15.68 | Upgrade
|
| Accrued Expenses | 82 | 96 | 62 | 70 | 47 | 27.85 | Upgrade
|
| Current Portion of Leases | 12 | 12 | 11 | 3 | - | - | Upgrade
|
| Current Income Taxes Payable | - | 1 | - | - | 2 | - | Upgrade
|
| Current Unearned Revenue | 71 | 85 | 91 | 97 | 102 | 74.57 | Upgrade
|
| Other Current Liabilities | 16 | 14 | 3 | 3 | 5 | 3.57 | Upgrade
|
| Total Current Liabilities | 210 | 226 | 184 | 193 | 166 | 121.67 | Upgrade
|
| Long-Term Debt | 118 | 48 | - | - | - | - | Upgrade
|
| Long-Term Leases | - | 99 | 110 | 117 | 117 | 15.24 | Upgrade
|
| Long-Term Unearned Revenue | 60 | 234 | 307 | 355 | 462 | 132.53 | Upgrade
|
| Other Long-Term Liabilities | 138 | 58 | 32 | 23 | 5 | 0.54 | Upgrade
|
| Total Liabilities | 526 | 665 | 633 | 688 | 750 | 269.99 | Upgrade
|
| Common Stock | 1,793 | 1,617 | 1,311 | 1,206 | 1,118 | 0.01 | Upgrade
|
| Additional Paid-In Capital | - | - | - | - | - | 830.44 | Upgrade
|
| Retained Earnings | -1,244 | -1,132 | -849 | -542 | -275 | -328.18 | Upgrade
|
| Comprehensive Income & Other | - | - | - | -7 | -1 | 0.04 | Upgrade
|
| Total Common Equity | 549 | 485 | 462 | 657 | 842 | 502.3 | Upgrade
|
| Shareholders' Equity | 549 | 485 | 462 | 657 | 842 | 502.3 | Upgrade
|
| Total Liabilities & Equity | 1,075 | 1,150 | 1,095 | 1,345 | 1,592 | 772.29 | Upgrade
|
| Total Debt | 130 | 159 | 121 | 120 | 117 | 15.24 | Upgrade
|
| Net Cash (Debt) | 797 | 833 | 745 | 1,018 | 564 | 713.4 | Upgrade
|
| Net Cash Growth | -18.51% | 11.81% | -26.82% | 80.50% | -20.94% | 278.93% | Upgrade
|
| Net Cash Per Share | 8.22 | 9.25 | 10.07 | 14.14 | 7.62 | 13.02 | Upgrade
|
| Filing Date Shares Outstanding | 106.43 | 105.84 | 90.86 | 73.01 | 71.06 | 70.88 | Upgrade
|
| Total Common Shares Outstanding | 106.4 | 92.2 | 75.5 | 72.9 | 70.78 | 65.11 | Upgrade
|
| Working Capital | 736 | 790 | 647 | 874 | 1,096 | 614.15 | Upgrade
|
| Book Value Per Share | 5.16 | 5.26 | 6.12 | 9.01 | 11.90 | 7.71 | Upgrade
|
| Tangible Book Value | 549 | 485 | 462 | 657 | 842 | 502.3 | Upgrade
|
| Tangible Book Value Per Share | 5.16 | 5.26 | 6.12 | 9.01 | 11.90 | 7.71 | Upgrade
|
| Machinery | - | 31 | 27 | 20 | 16 | 11.42 | Upgrade
|
| Construction In Progress | - | 1 | 1 | 4 | 2 | 2.34 | Upgrade
|
| Leasehold Improvements | - | 56 | 54 | 34 | 32 | 11.11 | Upgrade
|
Updated May 6, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.